Reifs Carmen María Alcántara, Salido-Vallejo Rafael, Garnacho-Saucedo Gloria María, Corte-Sánchez Sofía De la, González-Menchen Alberto, García-Nieto Antonio Vélez
Hospital Universitario Reina Sofía - Córdoba, Spain.
An Bras Dermatol. 2016 Sep-Oct;91(5):642-644. doi: 10.1590/abd1806-4841.20164322.
Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
塞扎里综合征是一种原发性皮肤T细胞淋巴瘤，其特征为红皮病、淋巴结病和循环中的非典型细胞三联征。新分子靶点的出现推动了诸如阿仑单抗等药物的研发，阿仑单抗是一种抗CD52单克隆抗体，在治疗该疾病方面已显示出有前景的结果。我们报告一例70岁男性难治性塞扎里综合征患者，使用阿仑单抗治疗后皮肤病变清除率达80%，血液学和影像学完全缓解。由于不良反应，治疗4个月后停药，随访13个月，患者显示持续缓解且无疾病进展。
